Stylli Stanley S, Kaye Andrew H
Department of Neurosurgery, 5th Floor Clinical Sciences Building, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria 3052, Australia.
J Clin Neurosci. 2006 Jul;13(6):615-25. doi: 10.1016/j.jocn.2005.11.014. Epub 2006 Mar 22.
Photodynamic therapy (PDT) has been investigated extensively in the laboratory for decades, and for over 25 years in the clinical environment, establishing it as a useful adjuvant to standard treatments for many cancers. A combination of both photochemical and photobiological processes occur that lead to the eventual selective destruction of the tumour cells. It is a potentially valuable adjuvant therapy that can be used in conjunction with other conventional therapies for the treatment of cerebral glioma. PDT has undergone extensive laboratory studies and clinical trials with a variety of photosensitizers (PS) and tumour models of cerebral glioma. Many environmental and genetically based factors influence the outcome of the PDT response. The biological basis of PDT is discussed with reference to laboratory and preclinical studies.
几十年来,光动力疗法(PDT)一直在实验室中得到广泛研究,并且在临床环境中也已研究了25年以上,这使其成为许多癌症标准治疗方法的有用辅助手段。光化学和光生物学过程相结合,最终导致肿瘤细胞被选择性破坏。它是一种潜在有价值的辅助疗法,可与其他传统疗法联合用于治疗脑胶质瘤。PDT已使用多种光敏剂(PS)和脑胶质瘤肿瘤模型进行了广泛的实验室研究和临床试验。许多环境和基于基因的因素会影响PDT反应的结果。本文参照实验室和临床前研究讨论了PDT的生物学基础。